Yahoo Web Search

Search results

1. Novo Nordisk A/S

   NYSE: NVO

   136.04

   Add to watchlist

   Sign in to add to watchlist

   Sign In

   +0.47 (+0.35%)

   At close: Fri. May 24, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed

   Full chart

   • 1D
   • 5D
   • 1M
   • 6M
   • YTD
   • 1Y
   • MAX

   • Open	134.50
     High	136.70
     Low	134.22

   • Mkt Cap	606.01B
     P/E (TTM)	47.24
     Div & Yield	1.37 & 1.01%

   • Prev. Close	135.57
     52 Wk. Low	75.56
     52 Wk. High	138.28

   More about NVO

   What analysts are saying

   Morningstar Bearish Published May 25 · With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the... Read more

   Top stories

   • BIIB
     -0.11%
   • NONOF
     -1.76%
   • NVO
     +0.35%
   • REGN
   • AMGN

   The Biggest Biotechnology Company in Europe

   Yahoo Finance · 6 hours ago

   

   • NVO
     +0.35%
   • NONOF
     -1.76%

   Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

   Yahoo Finance · 1 week ago

   

   • NONOF
     -1.76%
   • NVO
     +0.35%

   Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review

   Yahoo Finance · 5 days ago

   

   Related stocks

   • LLY
     Eli Lilly and Company
     LLY
     807.43
     -0.13%
   • NVS
     Novartis AG
     NVS
     100.53
     -0.57%
   • SMCI
     Super Micro Computer, Inc.
     SMCI
     883.88
     +4.31%
   • SNY
     Sanofi
     SNY
     48.54
     -0.94%
   • AZN
     AstraZeneca PLC
     AZN
     78.54
     +0.46%

   More on Yahoo Finance

2. stockanalysis.com › stocks › nvoNovo Nordisk A/S (NVO) Stock Price, Quote & News - Stock Analysis

   stockanalysis.com › stocks › nvo

   • Cached

   3 days ago · Get the latest information on Novo Nordisk A/S (NVO), a Danish pharmaceutical company that produces diabetes and obesity drugs. See the stock price, earnings, dividend, analysts' ratings, news and more.

3. seekingalpha.com › article › 4695766-novo-nordiskNovo Nordisk: Considerable Growth Beyond Ozempic

   seekingalpha.com › article › 4695766-novo-nordisk

   10 hours ago · Novo Nordisk has a long-term growth strategy, focusing on the development of new treatments for cardiovascular diseases. Read why I rate NVO stock a Buy.

4. finance.yahoo.com › news › where-novo-nordisk-10Where Will Novo Nordisk Be in 10 Years? - Yahoo Finance

   finance.yahoo.com › news › where-novo-nordisk-10

   • Cached

   2 days ago · Novo Nordisk (NYSE: NVO) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an incredible 527%, which dwarfs the S&P 500 's 182% gain during the same period.

5. www.fool.com › investing › 2024/05/18Is Novo Nordisk Stock a Millionaire Maker? | The Motley Fool

   www.fool.com › investing › 2024/05/18

   • Cached

   May 18, 2024 · Current Price. $131.89. Price as of May 17, 2024, 4:00 p.m. ET. Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two. Danish pharmaceutical company ...

6. www.marketscreener.com › quote › stockNovo Nordisk A/S Stock - MarketScreener.com

   www.marketscreener.com › quote › stock

   • Cached

   4 days ago · Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products.

   • 4.9/5 (26)

   • Brand: NOVO NORDISK A/S

7. People also ask

   Is Novo Nordisk (NVO) a good stock to buy?

   • Novo Nordisk (NYSE: NVO) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an incredible 527%, which dwarfs the S&P 500 's 182% gain during the same period. But it wasn't until 2022 that the stock really took off. Up until then, its returns were more comparable to that of the broader market.

   Where Will Novo Nordisk Be in 10 Years?

   finance.yahoo.com/news/where-novo-nordisk-10-years-131500838.html

   See all results for this question

   How much should you invest in Novo Nordisk?

   • Assuming Novo Nordisk stock grows at a rate of 13% for 25 years, your investment in the stock could grow to more than 21 times its original value. That means you would need to invest more than $47,000 in the healthcare stock today, which likely isn't a realistic option for most investors. Suppose you invested for 30 years instead.

   Is Novo Nordisk Stock a Millionaire Maker? | The Motley Fool

   www.fool.com/investing/2024/05/18/is-novo-nordisk-stock-a-millionaire-maker/

   See all results for this question

   Is Novo Nordisk a good buy?

   • Novo Nordisk is still a good buy at its elevated price, but investors should temper their expectations. With more competitors in the GLP-1 market in the future, it won't be as easy for the healthcare stock to generate such high returns in the next 10 years.

   Where Will Novo Nordisk Be in 10 Years?

   finance.yahoo.com/news/where-novo-nordisk-10-years-131500838.html

   See all results for this question

   Will Novo Nordisk's financials look better in the future?

   • Novo Nordisk's already strong financials could look even better in the future as the company's drugs have loads of potential. The company's high-profit margins make it likely that earnings will soar right along with sales. Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.

   Is Novo Nordisk Stock a Millionaire Maker? | The Motley Fool

   www.fool.com/investing/2024/05/18/is-novo-nordisk-stock-a-millionaire-maker/

   See all results for this question

8. www.bloomberg.com › quote › NOVOB:DCNOVOB: Novo Nordisk A/S Stock Price Quote - Copenhagen ...

   www.bloomberg.com › quote › NOVOB:DC

   • Cached

   2 days ago · Stock analysis for Novo Nordisk A/S (NOVOB:Copenhagen) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

9. www.reuters.com › markets › companiesNOVOb.CO - | Stock Price & Latest News | Reuters

   www.reuters.com › markets › companies

   3 days ago · Get Novo Nordisk A/S (NOVOb.CO) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.